Placebos without Deception: A Randomized Controlled Trial in Irritable Bowel Syndrome
Open accessThe DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Placebo treatment can significantly influence subjective symptoms. However, it is widely believed that response to placebo requires concealment or deception. We tested whether open-label placebo (non-deceptive and non-concealed administration) is superior to a no-treatment control with matched patient-provider interactions in the treatment of irritable bowel syndrome (IBS). METHODS: Two-group, randomized, controlled three week trial (August 2009-April 2010) conducted at a single academic center, involving 80 primarily female (70%) patients, mean age 47 ± 18 with IBS diagnosed by Rome III criteria and with a score ≥ 150 on the IBS Symptom Severity Scale (IBS-SSS). Patients were randomized to either open-label placebo pills presented as "placebo pills made of an inert substance, like sugar pills, that have been shown in clinical studies to produce significant improvement in IBS symptoms through mind-body self-healing processes" or no-treatment controls with the same quality of interaction with providers. The primary outcome was IBS Global Improvement Scale (IBS-GIS). Secondary measures were IBS Symptom Severity Scale (IBS-SSS), IBS Adequate Relief (IBS-AR) and IBS Quality of Life (IBS-QoL). FINDINGS: Open-label placebo produced significantly higher mean (±SD) global improvement scores (IBS-GIS) at both 11-day midpoint (5.2 ± 1.0 vs. 4.0 ± 1.1, p<.001) and at 21-day endpoint (5.0 ± 1.5 vs. 3.9 ± 1.3, p = .002). Significant results were also observed at both time points for reduced symptom severity (IBS-SSS, p = .008 and p = .03) and adequate relief (IBS-AR, p = .02 and p = .03); and a trend favoring open-label placebo was observed for quality of life (IBS-QoL) at the 21-day endpoint (p = .08). CONCLUSION: Placebos administered without deception may be an effective treatment for IBS. Further research is warranted in IBS, and perhaps other conditions, to elucidate whether physicians can benefit patients using placebos consistent with informed consent. TRIAL REGISTRATION: ClinicalTrials.gov NCT01010191.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The number-needed-to-treat was 11 which should be compared with 4 for ‘placebo without deception,259 7 for alosetron,260 8 for linaclotide261 and 14 for tegaserod.262”
From Intestinal microbiota in functional bowel disorders: a Rome foundation report (2013) · cites this paper as [259]
The cited source says what the claim attributes to it.
In the citing paper
“Several trials of psychological treatments for IBS have failed to show differential effects on symptoms when using attention control conditions [32,62-64], and a recent study showed that IBS patients even respond to open-label placebo [65].”
The cited source says what the claim attributes to it.
In the citing paper
“Kaptchuk and colleagues showed that an open label inactive placebo pill produced better outcomes in IBS patients compared to no treatment13.”
From Is ginger effective for the treatment of irritable bowel syndrome? A double blind randomized controlled pilot trial (2014) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Discovery of Grounded Theory; Strategies for Qualitative Research
Glaser, B. G., Strauss, A. L., & Strutzel, E. (1968) · Nursing Research · doi:10.1097/00006199-196807000-00014 · Cited by 39,449
Pharmacological interventions for somatoform disorders in adults
Kleinstäuber, M., Witthöft, M., Steffanowski, A., van Marwijk, H., Hiller, W., & Lambert, M. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010628.pub2 · Cited by 11,335
Cohen, J. (1992) · Psychological Bulletin · doi:10.1037//0033-2909.112.1.155 · Cited by 8,771
Collecting and Interpreting Qualitative Materials
Denzin, N. K., & Lincoln, Y. S. (2012) · Cited by 6,094
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.061 · Cited by 4,856
Functional bowel disorders and functional abdominal pain
Thompson, W. G., Longstreth, G. F., Drossman, D. A., Heaton, K. W., Irvine, E. J., & Müller-Lissner, S. A. (1999) · Gut · doi:10.1136/gut.45.2008.ii43 · Cited by 2,440 · cited 1×
“Participants were adults ($18 years old) meeting the Rome III criteria for IBS [17] with a score of $150 on the IBS Symptom Severity Scale (IBS-SSS).”
MethodFRANCIS, C. Y., MORRIS, J., & WHORWELL, P. J. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1997.142318000.x · Cited by 1,708 · cited 3×
“[18] The open-label group improved by 92 points on this measure; in addition, the improvement shown by the openlabel placebo group exceeded that shown by the no-treatment group by 46 points.”
MethodInfluentialIs the Placebo Powerless?: An Analysis of Clinical Trials Comparing Placebo with No Treatment
Hróbjartsson, A., & Gøtzsche, P. C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105243442106 · Cited by 1,503
AGA technical review on irritable bowel syndrome.
Drossman, D. A., Camilleri, M., Mayer, E. A., & Whitehead, W. E. (2002) · Gastroenterology · doi:10.1053/gast.2002.37095 · Cited by 1,384 · cited 1×
“[7,8] It is a chronic functional gastrointestinal disorder characterized by abdominal pain and discomfort associated with altered bowel habits.”
BackgroundBiological, clinical, and ethical advances of placebo effects
Finniss, D. G., Kaptchuk, T. J., Miller, F., & Benedetti, F. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61706-2 · Cited by 1,272
Self-citation
Research works printed but not linked: 1
- Vanner SJ Depew WT Paterson WG 2004 Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome and functional dyspepsia. Gut 53 666 72 · DOI · Paper page
Cited by
Items 501–600 of 897
Nocebo effects from negative product information: when information hurts, paying money could heal
Mukherjee, S., & Sahay, A. (2017) · Journal of Consumer Marketing · doi:10.1108/jcm-11-2015-1609 · Cited by 5
Introduction to Biomedical Ethics
Cook, J. T. (2020) · Springer eBooks · doi:10.1007/978-3-030-35660-6_1 · Cited by 5
Shah, E. D. (2021) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(21)00056-x · Cited by 5
Schiefke, I. (2021) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2021.33.005359 · Cited by 5
“Even open-label administration of placebo can produce significant improvements in IBS-SSS compared to no medication when the same level of physician interaction is provided [58].”
BackgroundTeenagers’ and parental attitudes towards the use of placebo pills
de Bruijn, C. M. A., Benninga, M. A., & Vlieger, A. M. (2023) · European Journal of Pediatrics · doi:10.1007/s00431-022-04801-4 · Cited by 5
Schöne-Seifert, B., Friedrich, D. R., & Reichardt, J.-O. (2015) · Zeitschrift für Evidenz Fortbildung und Qualität im Gesundheitswesen · doi:10.1016/j.zefq.2014.12.001 · Cited by 5
Walach, H. (2016) · Verhaltenstherapie · doi:10.1159/000453050 · Cited by 5
“Ted Kaptchuk und seine Gruppe [Kam-Hansen et al., 2014, Kelley et al., 2011; Kaptchuk et al., 2010] haben mittlerweile mehrfach gezeigt, dass Placebo, selbst wenn es offen gegen wird, also mit voller Aufklärung der Patienten, wirksam ist.”
BackgroundEarly treatment response affects signal detection in a placebo-controlled depression study
Targum, S. D., & Catania, C. J. (2017) · Personalized Medicine in Psychiatry · doi:10.1016/j.pmip.2017.10.001 · Cited by 5
Verhees, M. W. F. T., van IJzendoorn, M. H., Bakermans‐Kranenburg, M. J., Ceulemans, E., Winter, S. D., Santens, T., Alaerts, K., Casteels, K., Salemink, E., Verhaeghe, J., et al. (2019) · Journal of Behavior Therapy and Experimental Psychiatry · doi:10.1016/j.jbtep.2019.101514 · Cited by 6
Doleys, D. M. (2017) · Pain Physician · doi:10.36076/ppj/2017.7.e1095 · Cited by 7
Irritable Bowel Syndrome: Questions and Answers for Effective Care.
Wilkinson, J. M., & Gill, M. C. (2021) · PubMed · Cited by 14
Rhodes, J. R., Alldredge, C. T., & Elkins, G. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1204163 · Cited by 4
Swafford, A. P., Kwon, D. P., MacLennan, R. J., Fukuda, D. H., Stout, J. R., & Stock, M. S. (2019) · European Journal of Applied Physiology · doi:10.1007/s00421-019-04219-1 · Cited by 5
Greville-Harris, M., Bostock, J., Din, A., Graham, C. A., Lewith, G. T., Liossi, C., O’Riordan, T., White, P., Yardley, L., & Bishop, F. L. (2016) · JMIR Research Protocols · doi:10.2196/resprot.5627 · Cited by 6
“For example, despite strong evidence of placebo effects and mechanisms in the scientific literature, [4-7] only 1 of 45 leaflets explicitly stated that patients might experience beneficial effects from the placebo [3].”
Background[The expression of cMET/hepatocyte growth factor receptor in colorectal cancer].
Ajisaka, H., Nishimura, G., Tsuneda, A., Fujita, H., Michiwa, Y., Kawamura, T., Sato, T., Nojima, N., Fushida, S., Fujimura, T., et al. (1998) · PubMed · Cited by 6
Locher, C., Gaab, J., Blease, C. R., Inderbinen, M., Kost, L., & Koechlin, H. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00998 · Cited by 7
Smits, R. M., Veldhuijzen, D. S., van Middendorp, H., Muller, P. C. E. H., Armbrust, W., Legger, G. E., Wulffraat, N. M., & Evers, A. W. M. (2020) · Pediatric Rheumatology · doi:10.1186/s12969-020-0407-5 · Cited by 6
Commentary: the law, unproven CAM and the two‐hats fallacy
Caulfield, T. (2012) · Focus on Alternative and Complementary Therapies · doi:10.1111/j.2042-7166.2011.01135.x · Cited by 5
Carlino, E., & Benedetti, F. (2014) · Wiley eBooks · doi:10.1002/9781118453940.ch3 · Cited by 5
How to address the placebo response in the prescription SSRIs and SNRIs in children and adolescents
Koechlin, H., Kossowsky, J., Gaab, J., & Locher, C. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1475558 · Cited by 6
Vasovagal Syncope Needs the “Expert Touch”
Raj, S. R., & Sheldon, R. S. (2022) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2021.11.006 · Cited by 5
Bosch, D. H. C. A., Beckers, A. B., Snijkers, J. T. W., Bosman, M., Winkens, B., Muris, J. W. M., de Wit, N. J., Brouwers, J. R. B. J., van Hee, K., Clemens, C. H. M., et al. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.01.013 · Cited by 7
Can Nocebo Effects Be Reduced via Open‐ and Closed‐Label Counterconditioning?
Meijer, S., Evers, A. W. M., Peerdeman, K. J., & van Middendorp, H. (2026) · European Journal of Pain · doi:10.1002/ejp.70248 · Cited by 4
“Although open-label placebo procedures have been demonstrated to be effective (Carvalho et al. 2016; Kaptchuk et al. 2010; Kelley et al. 2012; Kleine-Borgmann et al. 2019; Locher et al. 2017; Meeuwis et al. 2019; Schaefer et al. 2016, 2018a), only one study investigated open-label…”
Skopp, N. A., Bradshaw, D. H., Smolenski, D. J., Wilson, N., Williams, T., Bellanti, D. M., & Hoyt, T. (2024) · Military Psychology · doi:10.1080/08995605.2023.2296333 · Cited by 5
“Mind-body practices have been described as “an effective form of intentional placebo without deception” because such practices use intention to heal (Hicks et al., 2016; Kaptchuk et al., 2010).”
Social pain: A systematic review on interventions
Brooks, B. M., Cordero, F. J., Alchermes, S. L., & Brooks, B. M. (2025) · F1000Research · doi:10.12688/f1000research.159561.1 · Cited by 3
Noble Humbug? Hard and soft laws on clinical placebo use
Richard, M., Ganz, M., Hornstein, L. D., Stehlik, B., Levy, M., Blease, C., Annoni, M., Elger, B. S., & Gaab, J. (2025) · Frontiers in Psychology · doi:10.3389/fpsyg.2025.1520664 · Cited by 4
Hackett, C., & Kolber, M. R. (2015) · Europe PMC (PubMed Central) · Cited by 4
The hardest thing to see is what is in front of your eyes – quo vadis placebo analgesia?
Conrad, R. (2016) · Journal of Pain Research · doi:10.2147/jpr.s122147 · Cited by 5
Biochemistry of Desire: The Biosemiotics of Advertising to Bacteria
Hendlin, Y. H. (2021) · Biosemiotics/Biosemiotics. Bookseries · doi:10.1007/978-3-030-67115-0_2 · Cited by 4
Choi, J. I., Lee, Y. L., & Lee, S. Y. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.990418 · Cited by 4
Open-label placebos reduce weight in obesity: a randomized controlled trial
Schaefer, M., Kühnel, A., & Enge, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-69866-7 · Cited by 5
“Then all participants were briefed about the placebo effect identical to previous research 30 .”
ResultThe use of placebo interventions in clinical practice
Linde, K. (2012) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2012.11.010 · Cited by 4
Vanninen, P., & Määttä, K. (2014) · Studies for the Learning Society · doi:10.2478/sls-2013-0003 · Cited by 4
“The studies have even shown that treatments have had a positive influence even if patients were told that their daily dose does not include medicine but placebo (Kaptchuk et al., 2010).”
BackgroundParmenides, Ontological Enaction, and the Prehistory of Rhetoric
Rickert, T. (2014) · Philosophy and Rhetoric · doi:10.5325/philrhet.47.4.0472 · Cited by 4
Mommaerts, J.-L., & Devroey, D. (2013) · Perspectives in biology and medicine · doi:10.1353/pbm.2013.0015 · Cited by 4
How to Deal with Pediatric Functional Gastrointestinal Disorders
Yacob, D., & Lorenzo, C. D. (2013) · Current Pediatrics Reports · doi:10.1007/s40124-013-0018-4 · Cited by 5
“The authors concluded that even placebos administered without deception constituted an effective treatment for IBS [20].”
BackgroundZinner, N. R., Ammann, L. P., Haas, G. P., Janning, S. W., He, W., & Bukofzer, S. (2012) · Neurourology and Urodynamics · doi:10.1002/nau.22313 · Cited by 4
Pizzorno, L. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4377-2333-5.00048-1 · Cited by 4
Cognitive structuring and placebo effect
Dolińska, B., Doliński, D., & Bar‐Tal, Y. (2017) · Personality and Individual Differences · doi:10.1016/j.paid.2017.06.030 · Cited by 5
Lanier, W. L., & Neal, J. M. (2019) · Regional Anesthesia & Pain Medicine · doi:10.1136/rapm-2019-100647 · Cited by 4
Choice over placebo administration enhances open-label placebo hypoalgesia
Tang, B., Livesey, E. J., & Colagiuri, B. (2023) · Pain · doi:10.1097/j.pain.0000000000003108 · Cited by 5
Schienle, A., Kogler, W., Seibel, A., & Wabnegger, A. (2024) · Social Cognitive and Affective Neuroscience · doi:10.1093/scan/nsae021 · Cited by 4
“Taken together, the self-report data question the common assumption that the actual intake of the pill is a crucial factor for OLP responses (Kaptchuk et al ., 2010).”
BackgroundAn Introduction to the Semiotic Approach to the Placebo Responses
Goli, F., Rafieian, S., & Atarodi, S. (2016) · Studies in neuroscience, consciousness and spirituality · doi:10.1007/978-3-319-35092-9_1 · Cited by 8
Equality, efficiency and effectiveness: going beyond RCTs in A. L. Cochrane's vision of health care
Trnka, S. H., & Stöckelová, T. (2018) · Sociology of Health & Illness · doi:10.1111/1467-9566.12817 · Cited by 4
Milgrom, L. R. (2014) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2013.0212 · Cited by 8
“…the other showing that placebos have meaningful clinical benefits in irritable bowel syndrome even when the patient knows they are receiving placebo 17 ) may be understood in terms of a previously described 18 complementary relationship between remedy and consultation, 19 similar to that found…”
Complexity Science in the Future of Behavioral Medicine
Pincus, D., & Guastello, S. J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4998-0_50 · Cited by 7
Liodden, I., Sandvik, L., & Norheim, A. J. (2015) · Complementary Medicine Research · doi:10.1159/000442565 · Cited by 5
Making Sense in the Medical System: Placebo, Biosemiotics, and the Pseudomachine
Schmidt, S., & Walach, H. (2016) · Studies in neuroscience, consciousness and spirituality · doi:10.1007/978-3-319-35092-9_8 · Cited by 4
Bialosky, J. E., & Robinson, M. E. (2017) · Journal of Manual & Manipulative Therapy · doi:10.1080/10669817.2017.1298699 · Cited by 5
Héron, A., Leroux, C., & Dubayle, D. (2019) · médecine/sciences · doi:10.1051/medsci/2019127 · Cited by 4
Saito, T., Barreto, G., Saunders, B., & Gualano, B. (2020) · Sports Medicine · doi:10.1007/s40279-020-01285-w · Cited by 5
Physician perspectives on placebo ethics
Bliamptis, J., & Barnhill, A. (2021) · Journal of Medical Ethics · doi:10.1136/medethics-2021-107446 · Cited by 4
Destigmatising the Placebo Effect
Arnold, M. H., Finniss, D. G., & Kerridge, I. (2015) · The American Journal of Bioethics · doi:10.1080/15265161.2015.1074312 · Cited by 4
Glannon, W. (2018) · Oxford University Press eBooks · doi:10.1093/med/9780198758853.003.0009 · Cited by 4
Sivin, N. (2015) · Asian Medicine · doi:10.1163/15734218-12341349 · Cited by 6
The Placebo Effect in Medicine and Clinical Practice: A Narrative Review
Tzigkounakis, G., Simati, K., & Georgiadis, K. (2025) · Cureus · doi:10.7759/cureus.91893 · Cited by 5
“Open-label placebo trials indicate that when the therapeutic rationale and ritual are explained clearly, patients may still experience meaningful benefits without deception [49-51].”
Moumeni, I. N., Moumeni, A.-N. N., Orlsiter, T. K. B., & Tsatedem, F. A. (2026) · Frontiers in Musculoskeletal Disorders · doi:10.3389/fmscd.2025.1716794 · Cited by 3
Improving Consumer Decisions: The Conscious Use of Primes as Performance Enhancers
Nicolao, L., Yorkston, E. A., Brocato, D., & Brei, V. A. (2016) · BAR - Brazilian Administration Review · doi:10.1590/1807-7692bar2016160020 · Cited by 4
“However, some recent work has shown that if the placebo is used as a prime for the power of positive thinking, then awareness of the effect does not cause it to disappear (Kaptchuk et al., 2010).”
BackgroundPatient Information on Evidence and Clinical Effectiveness of Psychotherapy
Blease, C. R., Kelley, J. M., & Trachsel, M. (2020) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780198817338.013.24 · Cited by 3
Self-citationFriehs, T., Milde, C., Glombiewski, J. A., & Κube, T. (2023) · European Journal of Pain · doi:10.1002/ejp.2216 · Cited by 3
“…which might have attracted a more heterogeneous sample than many other OLP studies that advertised ‘novel mind-body treatments’ which might attract mainly participants who are open minded towards new forms of interventions (Carvalho et al., 2016; Kaptchuk et al., 2010; Locher et al., 2017).”
BackgroundResultInfluentialWu, M.-C., & Stoessl, A. J. (2024) · Anesthesiology Clinics · doi:10.1016/j.anclin.2024.02.005 · Cited by 6
Ganju, J. (2025) · Pharmaceutical Statistics · doi:10.1002/pst.70015 · Cited by 3
“Much ado to know myself…”: Insight in the talking cures
Jopling, D. A. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06189.x · Cited by 3
The Ritual Effect: The Healing Response to Forms and Performs
Goli, F., & Farzanegan, M. (2016) · Studies in neuroscience, consciousness and spirituality · doi:10.1007/978-3-319-35092-9_5 · Cited by 4
The Placebo Drama of the Asclepius Cult
Panagiotidou, O. (2021) · Trends in Classics · doi:10.1515/tc-2021-0007 · Cited by 7
The Tangled Knots of Neuroscientific Experimentation
Frisch, S. (2021) · Integrative Psychological and Behavioral Science · doi:10.1007/s12124-021-09617-9 · Cited by 3
Meijer, S., van Middendorp, H., Peerdeman, K. J., & Evers, A. W. M. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.806409 · Cited by 3
“…literature on the use of counterconditioning (or related methods, such as systematic desensitization) in clinical care is limited in the field of fear and evaluative conditioning (Keller et al., 2020) and non-existent in nocebo research, it is difficult to determine the optimal number of sessions.”
BackgroundResultMüller, A., Konigorski, S., Meißner, C., Fadai, T., Warren, C. V., Falkenberg, I., Kircher, T. T. J., & Nestoriuc, Y. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-05184-y · Cited by 4
“The rationale comprises four discussion points: (1) the placebo effect is strong; (2) the body can automatically react to taking placebo pills; (3) a positive attitude helps but is not necessary; (4) a regular intake is necessary [21].”
InfluentialPaschke, L. M., Dreyer, N., Worm, M., & Klinger, R. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-074957 · Cited by 3
“42 However, not every study has found evidence that provision of detailed information about placebos influences the efficacy of OLP.”
BackgroundPredictability of placebo responses and their clinical implications
Branco, P., Vachon‐Presseau, É., Hall, K. T., Wager, T. D., & Apkarian, A. V. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780197645444.003.0005 · Cited by 3
A Fictionalist Account of Open-Label Placebo
Hardman, D. I. (2024) · The Journal of Medicine and Philosophy A Forum for Bioethics and Philosophy of Medicine · doi:10.1093/jmp/jhae008 · Cited by 6
“For example, in a randomised controlled trial in IBS testing whether OLP is better than no treatment (Kaptchuk et al. 2010), participants were first told that the study was for a novel mind-body management treatment, then told placebo pills have self-healing properties.”
BackgroundPotthoff, J., & Schienle, A. (2024) · Appetite · doi:10.1016/j.appet.2024.107820 · Cited by 3
Hanaway, P. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35868-2.00041-4 · Cited by 4
From Bench to Bedside: Converting Placebo Research into Belief Activation
Green, J., & Wright, H. (2017) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2016.0375 · Cited by 4
“17,20 In a controlled trial with migraine sufferers, the benefits of placebo persisted even when placebo was honestly described.”
Superstition predicts favorable weight change in an open-placebo trial: a prospective study
Rekhviashvili, N., & Gupta, S. V. (2014) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-014-0167-7 · Cited by 4
Uyei, J., & Braithwaite, R. S. (2015) · Medical Decision Making · doi:10.1177/0272989x15584770 · Cited by 3
“Fourth, it might be argued that the novel study design is unnecessary because a placebo effect might be obtained by disclosing to the patient that a placebo has been employed.(17) However, we postulate that even if this is true in the short term, it is unlikely to remain true in the long term, and therefore the novel…”
BackgroundReconstructing the Meaning Effect - The Capacity to Self-Heal Emerges From the Placebo Concept
Walach, H. (2016) · Tidsskrift for Forskning i Sygdom og Samfund · doi:10.7146/tfss.v12i23.23016 · Cited by 5
“Patients were briefed extensively about the fact that they were being enrolled in a trial where only placebo (trial 1) would be dispensed (Kaptchuk et al., 2010), or where (trial 2) they would receive various substances, among them potentially placebo and were told so (Kam-Hansen et al.”
BackgroundMethodInfluentialHypoalgesic placebo effects can occur with transparent disclosures
Colloca, L. (2017) · Pain · doi:10.1097/j.pain.0000000000001041 · Cited by 3
Cosgrove, L., & Vaswani, A. (2018) · Springer eBooks · doi:10.1007/978-3-030-02732-2_3 · Cited by 7
Manaï, M., van Middendorp, H., Veldhuijzen, D. S., van der Pol, J. A., Huizinga, T. W. J., & Evers, A. W. M. (2020) · Trials · doi:10.1186/s13063-019-3777-6 · Cited by 4
Der Schein trügt nicht – klinische Evidenz und neue Forschungsansätze zum Open-label-Placebo
Nestoriuc, Y., & Kleine‐Borgmann, J. (2020) · Der Nervenarzt · doi:10.1007/s00115-020-00953-6 · Cited by 3
Colagiuri, B., Sharpe, L., Ambarchi, Z., Glozier, N., Bartlett, D. J., Costa, D. S. J., & Scott, A. J. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-044045 · Cited by 3
Liu, T. (2021) · Clinical Psychological Science · doi:10.1177/21677026211009799 · Cited by 4
“, 2016), IBS (Kaptchuk et al., 2010; Lembo et al., 2021), allergic rhinitis (Schaefer et al.”
BackgroundInfluentialRifaximin for Irritable Bowel Syndrome without Constipation
Krause, R., Zollner‐Schwetz, I., & Valentin, T. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1101839 · Cited by 4
Justman, S. (2013) · Journal of the Royal Society of Medicine · doi:10.1177/0141076813489969 · Cited by 3
“In a study of irritable bowel patients, 35% achieved adequate relief despite receiving only supportive care, an arrangement they found so satisfactory that they were ‘not overly disappointed’ to be denied the active treatment – in this case, a placebo pill.(7) Care itself is the best placebo.”
BackgroundEditorial: Placebo Effect in Pain and Pain Treatment
Bernstein, M. H., Blease, C., & Vase, L. (2022) · Frontiers in Pain Research · doi:10.3389/fpain.2022.884055 · Cited by 3
Open-label placebo is an evidence-based treatment option for many chronic conditions
Ballou, S., & Κube, T. (2024) · Pain · doi:10.1097/j.pain.0000000000003145 · Cited by 3
Influence of Placebo Analgesia in Pharmacological Treatment of Pain
Sanders, D., Colloca, L., & Finniss, D. G. (2020) · Future Drug Discovery · doi:10.4155/fdd-2019-0028 · Cited by 2
Reverman, E. C. (2024) · Episteme · doi:10.1017/epi.2024.19 · Cited by 2
“2002, 2011; Kaptchuk et al .”
Side effects following administration of open-placebos: A randomized controlled trial
Faasse, K., Gasteiger, C., Borgmann, A., Choi, Y. J., & Petrie, K. J. (2024) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2024.112028 · Cited by 2
Nascimento, A. F., Bakis, B., Gaab, J., Schneider, T., Papadopoulou, A., Ritter, M., Bernstein, M. H., Blease, C. R., & Locher, C. (2025) · Frontiers in Psychology · doi:10.3389/fpsyg.2025.1533663 · Cited by 2
Open-label nondeceptive placebos
Kleine‐Borgmann, J., & Bingel, U. (2025) · Handbook of clinical neurology · doi:10.1016/b978-0-443-29884-4.00020-0 · Cited by 2
Schaefer, M., Liedtke, C., & Enge, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-27622-5 · Cited by 3
Camilleri, M. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.03.038 · Cited by 3
Liedtke, C., Schaefer, M., & Enge, S. (2026) · Scientific Reports · doi:10.1038/s41598-026-54791-8 · Cited by 3
“Adopted from previous OLP studies 22,25,26,52 , all participants were provided with a standardized written instruction describing the OLP rationale.”
Johnsen, P. H., Juul, F. E., Hoff, D. A. L., Hillestad, E. M. R., Holme, Ø., Skjevling, L. K., Hansen, H. M., Rasmus, M. H., Barnett, L., Barry, S. J. E., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01424-8 · Cited by 4
Information Assymetry and Double Standard in the Doctor-Patient Relationship
Janíčko, M., & Koubek, I. (2012) · Politická ekonomie · doi:10.18267/j.polek.854 · Cited by 2
Underappreciated power. Placebo and nocebo in medicine
Bueverov, A. O. (2020) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2020-4-162-167 · Cited by 5
The Ethics of Placebo and Nocebo in Psychotherapy
Gaab, J., Locher, C., & Trachsel, M. (2021) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780198817338.013.32 · Cited by 3
The role of superstition in the placebo effect on memory performance
An, S., Malani, V. D., & Setia, A. (2021) · Cognitive Processing · doi:10.1007/s10339-021-01025-6 · Cited by 2
Metadata
- Authors
- Kaptchuk, T. J., Friedlander, E., Kelley, J. M., Sanchez, M. N., Kokkotou, E., Singer, J. P., Kowalczykowski, M., Miller, F. G., Kirsch, I., & Lembo, A. J.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- National Institutes of Health (US)
- University of Hull (GB)
- Corresponding author
- Kaptchuk, Ted J.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-12-22
- Volume
- 5
- Issue
- 12
- Pages
- e15591
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3008733
- OpenAlex
- W2105330971
- Semantic Scholar
- 3d8aac4fba0e556c2d0898ad83cd3df11576e90c
- Cited by
- 900
- References
- 43
- Citations by year
- 2026: 28 · 2025: 44 · 2024: 48 · 2023: 56 · 2022: 55 · 2021: 67 · 2020: 72 · 2019: 55 · 2018: 97 · 2017: 48 · 2016: 55 · 2015: 55 · 2014: 65 · 2013: 48 · 2012: 58
- FWCI
- 29.43
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion, public-domain)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- U.S. Department of Health and Human Services
- Bernard Osher Foundation
- National Institutes of Health (5r01at000402-04)
- Japan Society for the Promotion of Science (13J11021)
- National Center for Complementary and Alternative Medicine
- National Center for Complementary and Integrative Health (R01AT004662, K24AT004095, R01 AT00402-01)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Complementary and alternative medicine › Acupuncture Treatment Research Studies
- Keywords
- irritable bowel syndrome, placebo effect, open-label placebo, symptom severity, quality of life, patient-provider interaction, informed consent
- MeSH terms
- Adult, Female, Humans, Deception, Male, Middle Aged, Placebos, Time Factors, Treatment Outcome, Patient Satisfaction, Irritable Bowel Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

